



Attorney Docket No.: 26230

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

DIETRICH, et al.

Serial No.: 10/505,138

Group Art: 1615

Filed: August 19, 2004

Examiner: SILVERMAN, E.

For: **ORAL DOSAGE FORM CONTAINING A PDE 4 INHIBITOR AS AN ACTIVE
INGREDIENT AND POLYVINYLPYRROLIDON AS EXCIPIENT**

REQUEST FOR

CONTINUED EXAMINATION (RCE)

TRANSMITTAL

Commissioner for Patents
Box RCE
P.O. Box 1450
Alexandria, VA 22313-1450

Application No.	10/505,138
Filing Date:	August 19, 2004
Title:	ORAL DOSAGE FORM CONTAINING A PDE 4 INHIBITOR AS AN ACTIVE INGREDIENT AND POLYVINYLPYRROLIDON AS EXCIPIENT
Inventor:	DIETRICH, et al.
Group Art Unit:	1615
Examiner:	SILVERMAN, E.
Atty Docket No.:	26230

Sir:

This is a Request for Continued Examination (RCE) under 37 C.F.R § 1.114 of the above-identified application.

Note: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application and Provisional Application Practice, Final Rule 65 Fed.Reg. 50092 9Aug. 16, 2000; Interim Rule, 65 Fed. Reg. 14865 (mar. 20, 2000), 1233 Off.Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice

08/30/2007 MAHRED1 00000031 10505138
01 FC:1801

790.00 00

a. Previously submitted

- ## 2. Miscellaneous

- ### 3. Fees

1. X The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Act. No. 14-0112.

- Date: August 29, 2007

Respectfully submitted,
THE NATH LAW GROUP

GMN:JBG:\RCE2.doc